Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
|Videos|August 19, 2022
The Changing Landscape of Digital Trials
Author(s)Veeva Systems
Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
Advertisement
- It is important to not get caught up on the terminology involved in the new landscape for clinical trials; digital is the how while decentralized is where a trial is done.
- The patient experience within digital trials can be improved by streamlining information and access into a single application.
- Veeva takes an end-to-end approach with clinical trials so patients can participate in them, while taking into consideration their routines and lifestyles.
Advertisement
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Advertisement
Advertisement
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5